Question? Call us
212-363-7500Expired
Lead Plaintiff Deadline
Sep 24, 2024
Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.
During the class period, Defendants made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. On May 9, 2024, the investing public learned that the drug was significantly more dangerous than defendants had previously represented. Following this news, MGNX’s stock declined 77.4% due to a drop of $11.36/share.
In order to be eligible to join the MGNX class action lawsuit, you must have incurred a loss on shares of MacroGenics purchased during the class period listed above.
If you suffered a loss in MacroGenics during the relevant time frame or pursuant to the relevant offering(s), you have until September 24, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
TOP